NEW YORK, Sept. 9, 2026 — Luma Group (“the Firm”), a New York-based investment firm focused on life sciences, today announced the successful final close of LumaBio I LP (“LumaBio Fund I” or “the Fund”), its inaugural life sciences venture capital fund, with $410 million in committed capital. LumaBio Fund I is backed by a global investor base, including leading financial institutions, sovereign wealth funds, insurance companies, family offices and ultra-high-net-worth individuals.
Luma Group was founded on the simple conviction that the convergence of biology, chemistry, physics and artificial intelligence will fundamentally reshape medicine. As scientific understanding deepens and computational capabilities continue to accelerate discovery and development, the Firm believes that the next generation of life sciences companies will emerge with the potential to transform patient care and improve human health.
Structured as a 15-year investment vehicle, the Fund plans to invest early alongside exceptional entrepreneurs and groundbreaking science, with the flexibility to support its highest-conviction companies through key milestones from discovery to commercialization.
“We founded Luma Group on the belief that extraordinary science, supported by patient, long-term capital, has the power to improve millions of lives,” said Joshua Fink, Founder and Managing Member of Luma Group. “This Fund represents more than capital – it is a commitment to partnering with extraordinary innovators as they translate visionary science into life-changing medicines. That commitment is made possible by the trust and confidence of our investors.”
“The coming decade will fundamentally reshape medicine as once-distinct scientific disciplines converge and the pace of discovery and translation accelerates,” added Themasap Khan, PhD, Co-Founder and Partner of Luma Group.
Since its inception in 2023, LumaBio Fund I has invested in companies with the potential to transform medicine, including Aeovian Pharmaceuticals, Altos Labs, Arsenal Biosciences, Character Biosciences, Coultreon Biopharma, Curve Biosciences, Integrated Biosciences, SciThera, Vaccine Company and several others in stealth.
Earlier this year, LumaBio Fund I announced its first exit with the acquisition of Vaccine Company by Eli Lilly and Company in a transaction valued at up to $1.55 billion. This transaction reflects the Firm’s strategy of identifying differentiated scientific platforms early and partnering closely with management teams through key value-creation milestones.
About Luma Group
Luma Group is a New York–based investment firm focused on the life sciences. The Firm combines scientific expertise, computational insight and a proprietary artificial intelligence platform to inform its investment strategy and support the companies that the Firm identifies, builds and backs. Luma Group partners with founders advancing transformative scientific and clinical innovation across the global life science ecosystem.
Media Contacts
Bill Ryan
Chief Financial Officer, Luma Group
[email protected]
Richie Santry
Chief of Staff, Luma Group
[email protected]
SOURCE Luma Group
